Novogene Europe expands single-cell RNA sequencing capability at Cambridge Omics Centre
Novogene Europe expands single-cell RNA sequencing services at its Cambridge Omics Centre to support advanced multiomics research
3 Aug 2026Novogene Europe has expanded its single-cell RNA sequencing capability at the Cambridge Omics Centre in Cambridge, UK. The enhanced service provides academic, biotech and biopharma researchers in the UK with direct access to specialist project support, 10x Genomics Chromium Single Cell-based workflows, sequencing infrastructure and bioinformatics expertise, helping them generate deeper biological insight from complex samples and meet growing demand for accessible single-cell transcriptomics.
Cambridge Omics Centre – a UK multiomics hub
Novogene Europe launches single-cell RNA sequencing service at Cambridge Omics Centre
The expansion of single-cell sequencing capability at the Cambridge Omics Centre follows the launch of Novogene Europe’s Untargeted Metabolomics Service at the same site. Together, these developments mark the next step in a broader phase of capability expansion at the Cambridge Omics Centre.
This investment further strengthens the Cambridge Omics Centre as a UK hub for advanced multiomics services and reflects Novogene Europe’s continued commitment to building local scientific capability and customer support for researchers across the region.
Single-cell RNA sequencing service
Novogene Europe’s Cambridge single-cell RNA sequencing service initially focuses on 3′ gene expression using cells or nuclei. The workflows are built around the 10x Genomics Chromium platform and are supported by GEM-X chemistry, high-throughput Illumina sequencing and Novogene Europe’s bioinformatics expertise.
The service covers the full workflow, including sample processing, quality control, library preparation, sequencing and comprehensive bioinformatics analysis. It is designed to support research across oncology, immunology, neuroscience, stem cell biology, developmental biology and translational research, as well as biomarker and drug discovery.
Enabling deeper insight into cellular heterogeneity
By profiling gene expression at single-cell or single-nucleus resolution, the expanded service enables researchers to explore cellular heterogeneity, identify rare cell populations and investigate how different cell types and states contribute to biological function.
Beyond the new capability at the Cambridge Omics Centre, Novogene Europe’s wider single-cell portfolio includes 5′ gene expression and single-cell immune profiling with T-cell receptor (TCR) and B-cell receptor (BCR) sequencing.
“Single-cell sequencing is helping researchers study complex biological systems with a level of detail that is difficult to achieve using bulk approaches alone,” said Tingting Zhou, VP of Novogene Europe. “By expanding access to single-cell sequencing workflows through our Cambridge Omics Centre, we are strengthening local support for UK researchers working across areas such as oncology, immunology, neuroscience, developmental biology and translational research.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What single-cell RNA sequencing services does Novogene Europe offer at the Cambridge Omics Centre?
Novogene Europe provides a single-cell RNA sequencing service in Cambridge focused initially on 3′ gene expression using cells or nuclei. The workflows are built on the 10x Genomics Chromium platform with GEM-X chemistry, high-throughput Illumina sequencing and comprehensive bioinformatics analysis, covering sample processing, QC, library preparation and sequencing for UK academic, biotech and biopharma researchers.
How does the Cambridge Omics Centre support multiomics research for UK and European scientists?
The Cambridge Omics Centre serves as a UK hub for advanced multiomics services. Novogene Europe has expanded single-cell RNA sequencing and launched an Untargeted Metabolomics Service at the site, strengthening local research infrastructure and supporting oncology, immunology, neuroscience, developmental biology and translational research across the region.
What research applications are enabled by Novogene Europe’s single-cell and multiomics expertise?
Novogene Europe’s expanded single-cell RNA sequencing capability enables profiling of gene expression at single-cell or single-nucleus resolution to study cellular heterogeneity and rare cell populations. Together with its broader single-cell portfolio, including 5′ gene expression and TCR/BCR immune profiling, and untargeted metabolomics, the company supports biomarker discovery, drug discovery and multiomics research in oncology, immunology, neuroscience and stem cell biology.